Ute Hoch

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Deborah H. Charych, Ute Hoch, John L. Langowski et al. · Clinical Cancer Research · 2016 · 392 citations

Life Sciences, Immunology, Oncology +17

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel et al. · Cancer Discovery · 2020 · 238 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Salah-Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez et al. · Cancer Discovery · 2019 · 232 citations

Life Sciences, Immunology, Pharmacology +17

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Wei-Gang Tong, Rong Chen, William Plunkett et al. · Journal of Clinical Oncology · 2010 · 218 citations

Medicine, Oncology, Pharmacology +17

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Meenu Sharma, Hiep Khong, Faisal Fa’ak et al. · Nature Communications · 2020 · 169 citations · Full text

Medicine, Immunology, Oncology +17